CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Tarsier Pharma Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Tarsier Pharma Ltd
HaMa'apilim St 10
ZIKHRON YA`AQOV, 3094238  Israel
Business Summary
Tarsier Pharma Ltd is an Israel-based biopharmaceutical company. The Company is focused on developing and commercializing novel immunomodulatory therapies for the treatment of autoimmune and inflammatory ocular diseases. The Company’s platform is based on dazdotuftide (TRS), a bio-inspired molecule designed to re-engineer immune responses and address underlying inflammatory pathways associated with eye disorders. The Firm targets conditions such as non-infectious anterior uveitis, uveitic glaucoma and other inflammatory eye diseases, with drug candidates being developed for administration via eye drops and intravitreal injections. The Company aims to provide safer and more effective alternatives to existing treatments for conditions that can lead to vision loss and blindness and affect a large global patient population.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202512/31/2025YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairperson of the Board, Chief Executive Officer DaphneHaim-Langford 52 6/1/2020 6/1/2020
Chief Financial Officer ArieGanot 65 2/1/2016 2/1/2016
Chief Operating Officer ZoharMilman 40 3/1/2017 3/1/2017
5 additional Officers and Directors records available in full report.

General Information
Number of Employees: 3 (As of 12/31/2025)
Stock Exchange: NYSE


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, July 30, 2026